Last reviewed · How we verify

NCT05682924

Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib

Recruiting now Last updated 16 December 2024
What this trial tests

trial testing taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry in Chronic Myeloid Leukaemia in 105 participants. Currently enrolling.

Timeline
1 October 2022
Primary endpoint
1 September 2025
15 September 2025

Quick facts

Lead sponsorSamara State Medical University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment105
Start date1 October 2022
Primary completion1 September 2025
Estimated completion15 September 2025
Sites2 locations across Russia

Drugs / interventions tested

Conditions studied

Sponsor

Samara State Medical University

Who can join

Adults 40 to 60, any sex, with Chronic Myeloid Leukaemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will study the state of the endothelium in patients with chronic myeloid leukemia during therapy with the II generation tyrosine kinase inhibitor bosutinib. Patients will be divided into groups receiving nilotinib 800mg/day, bosutinib 500mg/day, and imatinib 600mg/day. A comprehensive examination of patients will be carried out, including a clinical examination, a study of biochemical markers of endothelial damage and the functional state of the vascular wall. An algorithm will be developed for assessing the state of endothelial function in patients with ph-positive chronic myeloid leukemia in the chronic phase when using the second-generation tyrosine kinase inhibitor bosutinib.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Samara State Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05682924.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing